Asset profile
Olezarsen · Tryngolza
RNA / oligonucleotide
Evidence outlook
Approved: Familial Chylomicronemia Syndrome
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Atherosclerotic Cardiovascular Disease · Phase 3Severe Hypertriglyceridemia · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 62 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Olezarsen (Tryngolza): this drug | Approved | RNA / oligonucleotide | APOC3 | ||
| Plozasiran (Redemplo) | Approved | RNA / oligonucleotide | APOC3 | ||
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | ||
| RBD5044 | Phase 2 | RNA / oligonucleotide | APOC3 | ||
| RN0361 | Phase 1/2 | RNA / oligonucleotide | APOC3 | ||
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | ||
| Kylo-12 | Phase 1 | Small molecule | APOC3 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.